Stephane Bancel - Mar 16, 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Stock symbol
MRNA
Transactions as of
Mar 16, 2022
Transactions value $
-$3,134,688
Form type
4
Date filed
3/18/2022, 04:07 PM
Previous filing
Mar 11, 2022
Next filing
Mar 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Sale -$30.2K -200 0% $150.93 5.51M Mar 16, 2022 Direct F1, F2
transaction MRNA Common Stock Sale -$76.8K -500 -0.01% $153.52 5.51M Mar 16, 2022 Direct F1, F3
transaction MRNA Common Stock Sale -$15.4K -100 0% $154.49 5.51M Mar 16, 2022 Direct F1
transaction MRNA Common Stock Sale -$15.6K -100 0% $155.65 5.51M Mar 16, 2022 Direct F1
transaction MRNA Common Stock Sale -$110K -700 -0.01% $157.41 5.51M Mar 16, 2022 Direct F1, F4
transaction MRNA Common Stock Sale -$63.2K -400 -0.01% $158.12 5.51M Mar 16, 2022 Direct F1, F5
transaction MRNA Common Stock Sale -$44.7K -280 -0.01% $159.51 5.51M Mar 16, 2022 Direct F1, F6
transaction MRNA Common Stock Sale -$160K -1K -0.02% $160.40 5.51M Mar 16, 2022 Direct F1, F7
transaction MRNA Common Stock Sale -$129K -800 -0.01% $161.56 5.5M Mar 16, 2022 Direct F1, F8
transaction MRNA Common Stock Sale -$228K -1.4K -0.03% $162.63 5.5M Mar 16, 2022 Direct F1, F9
transaction MRNA Common Stock Sale -$229K -1.4K -0.03% $163.58 5.5M Mar 16, 2022 Direct F1, F10
transaction MRNA Common Stock Sale -$145K -879 -0.02% $164.69 5.5M Mar 16, 2022 Direct F1, F11
transaction MRNA Common Stock Sale -$49.7K -300 -0.01% $165.57 5.5M Mar 16, 2022 Direct F1, F12
transaction MRNA Common Stock Sale -$50.1K -300 -0.01% $167.00 5.5M Mar 16, 2022 Direct F1, F13
transaction MRNA Common Stock Sale -$101K -600 -0.01% $168.03 5.5M Mar 16, 2022 Direct F1, F14
transaction MRNA Common Stock Sale -$6.94K -41 0% $169.19 5.5M Mar 16, 2022 Direct F1
transaction MRNA Common Stock Gift -4K -0.07% 5.5M Mar 16, 2022 Direct F15, F16
transaction MRNA Common Stock Sale -$1.68M -10K -0.14% $168.00 6.97M Mar 17, 2022 See Footnote F17, F18
holding MRNA Common Stock 9.05M Mar 16, 2022 See Footnote F19
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.52 to $151.33. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.17 to $153.88. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.77 to $157.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.85 to $158.40. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.86 to $159.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.98 to $160.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F8 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.07 to $162.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F9 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.10 to $163.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F10 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.13 to $163.99. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F11 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.34 to $165.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F12 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.35 to $165.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F13 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.58 to $167.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F14 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $167.74 to $168.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F15 The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended May 13, 2021.
F16 The reported disposition represents a bona fide charitable gift made by the reporting person.
F17 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019.
F18 These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F19 These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.